Search
-
News
Read about MSK research that sheds light on how the innate immune system interacts with developing cancer cells.
… Monday, October 6, 2025 Understanding the interaction between immune cells and cancer cells has important implications for cancer immunotherapies , including checkpoint inhibitor drugs and cell-based therapies, as well as newer treatments like cancer vaccines . Over the last decade, computational
-
News
Isabel Lam, a 2016 alumnae of Gerstner Sloan Kettering, has been awarded the Chairman’s Prize for her first-author paper “Nonparadoxical evolutionary stability of the recombination initiation landscape in yeast,” published in Science in 2015.
… Friday, July 29, 2016 Isabel Lam , a 2016 alumnae of Gerstner Sloan Kettering, has been awarded the Chairman’s Prize for her first-author paper “ Nonparadoxical evolutionary stability of the recombination initiation landscape in yeast ,” published in Science in 2015. Isabel completed her graduate research
-
News
Learn the keys to a successful telemedicine visit from a cancer specialist at Memorial Sloan Kettering.
… Wednesday, May 27, 2020 Summary A Memorial Sloan Kettering cancer expert gives tips to patients on how they can be their own best advocates and feel confident, relaxed, and in control during telemedicine video visits with their cancer doctors. People with cancer and their doctors build a strong relationship
-
News
Aprenda las claves para una visita de telemedicina exitosa de parte de una especialista en cáncer en Memorial Sloan Kettering.
… Wednesday, May 27, 2020 Resumen Una experta en cáncer de Memorial Sloan Kettering da consejos a los pacientes sobre cómo pueden ser sus mejores defensores y sentirse seguros, relajados y en control durante las visitas de telemedicina por video con sus médicos especialistas en cáncer. Las personas con
-
News
Узнайте о том, что необходимо для успешного дистанционного приема, от онколога центра Memorial Sloan Kettering.
… Wednesday, May 27, 2020 Краткое изложение Специалист по онкологии из центра Memorial Sloan Kettering дает советы пациентам по поводу того, как наилучшим образом представлять свои интересы, чувствовать себя уверенно и спокойно и сохранять контроль над ситуацией во время дистанционного видеоприема у врача-онколога
-
News
A new discovery made by Memorial Sloan Kettering researchers and published in the journal Nature Genetics, identifies a mechanism for the triggering of solid tumors — including most types of cancers that affect children and young adults. For more information or to arrange interviews, e-mail Rebecca Williams at [email protected].
… Monday, May 15, 2017 Bottom Line : A new discovery published in the journal Nature Genetics identifies a mechanism for the triggering of solid tumors — including most types of cancers that affect children and young adults. The enzyme made by the gene PGBD5 cuts DNA segments and then rearranges them.
-
News
Cancer progression is commonly thought of as a process involving the growth of a primary tumor followed by metastasis, in which cancer cells leave the primary tumor and spread to distant organs. A new study by researchers at Memorial Sloan Kettering Cancer Center shows that circulating tumor cells - cancer cells that break away from a primary tumor and disseminate to other areas of the body - can also return to and grow in their tumor of origin, a newly discovered process called "self-seeding."
… Thursday, December 24, 2009 Cancer progression is commonly thought of as a process involving the growth of a primary tumor followed by metastasis, in which cancer cells leave the primary tumor and spread to distant organs. A new study by researchers at Memorial Sloan Kettering Cancer Center shows that
-
News
… Friday, November 8, 2024 Memorial Sloan Kettering Cancer Center (MSK) issued the following statement regarding its financial results for the first three quarters of 2024: MSK’s financial performance through the third quarter of 2024 demonstrate positive and consistent financial results, with an excess
-
News
New data from researchers at MSK featured in the 2022 ASCO Annual Meeting press program and simultaneously published in The New England Journal of Medicine highlights a novel antibody-drug conjugate that doubled progression-free survival in HER2-low metastatic breast cancer.
… Sunday, June 5, 2022 Update: On August 5, 2022, the FDA approved the first targeted therapy for patients with HER2-low breast cancer that has spread to other parts of the body and is unable to be surgically removed. The drug, https://www.mskcc.org/cancer-care/patient-education/fam-trastuzumab-deruxtecan
-
News
Seven students will be awarded PhD degrees on May 19, 2021, from the Gerstner Sloan Kettering Graduate School of Biomedical Sciences (GSK), an innovative doctoral program that prepares the next generation of basic laboratory scientists to work in research areas related to human disease with a focus on cancer.
… Monday, May 17, 2021 Seven students will be awarded PhD degrees on May 19, 2021, from the Gerstner Sloan Kettering Graduate School of Biomedical Sciences (GSK) , an innovative doctoral program that prepares the next generation of basic laboratory scientists to work in research areas related to human